Effects of fenofibrate therapy on renal function in primary gout patients.

Xinde LiWenyan SunJie LuYuwei HeYing ChenWei RenLingling CuiZhen LiuCan WangXuefeng WangLidan MaXiaoyu ChengLin HanHailong LiHui ZhangXuan YuanXiaopeng JiAichang JiTony Raymond MerrimanChanggui Li

Published in: Rheumatology (Oxford, England) (2021)

This observational study implied that fenofibrate-associated nephrotoxicity occurs frequently in gout patients, especially in patients with tophi or CKD. The potential renal risks of fenofibrate usage in gout needs additional research.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
prognostic factors
metabolic syndrome
risk assessment
mesenchymal stem cells
bone marrow
smoking cessation